1070 related articles for article (PubMed ID: 6601174)
1. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.
Ballas ZK; Rasmussen W; van Otegham JK
J Immunol; 1987 Mar; 138(5):1647-52. PubMed ID: 2879870
[TBL] [Abstract][Full Text] [Related]
7. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
8. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
10. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
Thiele DL; Lipsky PE
J Immunol; 1986 Aug; 137(4):1399-406. PubMed ID: 3488348
[TBL] [Abstract][Full Text] [Related]
11. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
Phillips JH; Lanier LL
J Exp Med; 1986 Sep; 164(3):814-25. PubMed ID: 3489062
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
13. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Int J Cancer; 1989 May; 43(5):940-8. PubMed ID: 2469657
[TBL] [Abstract][Full Text] [Related]
14. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function.
Zocchi MR; Bottino C; Ferrini S; Moretta L; Moretta A
J Exp Med; 1987 Aug; 166(2):319-26. PubMed ID: 3598463
[TBL] [Abstract][Full Text] [Related]
15. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
16. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
17. T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells.
Moretta L; Pende D; Cozzani R; Merli A; Bagnasco M; Mingari MC
Eur J Immunol; 1986 Dec; 16(12):1623-5. PubMed ID: 3102249
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Fox BA; Rosenberg SA
Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells.
Bagnasco M; Mingari MC; Pende D; Venuti D; Canonica GW; Moretta L
Int J Cancer; 1987 Jun; 39(6):703-7. PubMed ID: 3108168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
